Shield Therapeutics and Viatris sign collaborative sales agreement for Accrufer in the United States.
Shield Therapeutics plc, a commercial stage pharmaceutical company focused on the commercialization of Accrufer/Feraccru (ferric maltol), announced that it has entered into an exclusive, multi-year agreement with Viatris Inc. to co-commercialize Accrufer (ferric maltol), a novel, oral iron therapy differentiated from other conventional irons by its efficacy, well-tolerated formulation, and broad indication, in the United States
The oral iron market in the United States is an estimated $2 billion market opportunity, and Accrufer is the only FDA approved oral iron to treat iron deficiency, with or without anemia. This new collaboration expands the commercial footprint and resources for Accrufer, as the brand aspires to be the oral iron of choice in the US market. The collaboration will result in a 100 person sales team who will promote Accrufer to over 12,000 Health Care Professionals who write the majority of oral iron prescriptions. In addition, Shield and Viatris will also deploy additional resources in digital marketing, market access, distribution and commercial operations via a shared cost model.
340 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.